License agreement with Janssen clears Yesintek market entry in additional global markets
Biocon has signed a license agreement with Janssen Sciences Ireland that clears the way to commercialise Yesintek™, its proposed biosimilar to Stelara® (Ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand.
By ScoutQuest · · 1 min read
- Markets added
- Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan
- Reference brand worldwide sales
- $6.08 billion in 2025
- Earlier agreement coverage
- the US, Europe, the UK, Canada and Japan
Biocon has signed a license agreement with Janssen Sciences Ireland that clears the way for the commercialisation of Yesintek™, its proposed biosimilar to Stelara® (Ustekinumab), in a set of additional markets with immediate effect.
Markets added
- Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan.
How this fits with earlier deals
- The company states this milestone builds on previously announced agreements with Janssen that secured market entry dates for Yesintek™ in the United States, and in Europe, the UK, Canada and Japan.
What the product is
- Yesintek™ is a human interleukin-12 and -23 antagonist that disrupts IL-12 and IL-23 mediated signalling in immune mediated diseases.
- It has been approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
Size of the reference brand
- Stelara®, the reference brand, had worldwide sales of $6.08 billion in 2025, as per Johnson & Johnson's reported 2025 sales.
Points to note
- The company describes Yesintek™ as a proposed biosimilar.
- Product launches in all the countries or regions mentioned are subject to regulatory approval.
- The statement says these additional market entry rights will allow Biocon to offer an affordable and effective treatment option for patients impacted by autoimmune diseases in these markets.
Also from Biocon
Biocon to hold Q2 FY2026-27 earnings conference call with analysts and investors on November 4, 2026
26 Oct 2026
Board meeting on Nov 4 to approve Q2 results, analyst call the same day
26 Oct 2026
Global patent settlement with Genentech secures earliest licensed launch dates for Pebrilzo® (bPertuzumab)
14 Oct 2026
More numbers
- Stelara worldwide sales in 2025$6.08 billion
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.